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Protein phosphatase 1 binds to phospho-Ser-1394 of the
macrophage-stimulating protein receptor
Massimo M. SANTORO*, Giovanni GAUDINO* and Emma VILLA-MORUZZI†1
*Department of Medical Sciences, University of Piemonte Orientale ‘A. Avogadro’, 28100 Novara, Italy, and †Department of Experimental Pathology, University of Pisa,
via Roma 55, 56126 Pisa, Italy
The tyrosine kinase Ron, receptor for MSP (macrophage-stimu-
lating protein), displays several serine residues of unknown
functions. Using [32P]H3PO4 metabolic labelling, we found that
Ron is serine-phosphorylated and dephosphorylated in vitro by
PP1 (protein phosphatase 1). PP1 associates with Ron obtained
from cells of different origins. The association is stimulated by
MSP or serum and is prevented by wortmannin, an inhibitor
of the Akt/PKB (protein serine/threonine kinase B) pathway.
Akt/PKB phosphorylates Ron Ser-1394, thus providing a docking
site for 14-3-3 (scaffold proteins binding to phosphoserine/phos-
phothreonine-containing sequences). In living cells, PP1 binds to
the Ron mutant S1394A, but the association is no longer regulated
by serum, MSP or wortmannin. The role of PP1 association with
Ron is highlighted by (1) Ser-1394 dephosphorylation by PP1
in vitro and in living cells, (2) loss of 14-3-3 association with
Ron after Ser-1394 dephosphorylation by PP1 in vitro and (3) an
increase in 14-3-3 association after PP1 inactivation in living cells.
These results suggest that PP1 can modulate the downstream Ron
signalling generated by MSP via Akt/PKB and 14-3-3 binding.
This is the first report on ligand-regulated association of PP1 with
a growth factor receptor.
Key words: Akt/protein serine/threonine kinase B (PKB),
macrophage-stimulating protein (MSP), protein phosphatase,
protein phosphorylation, receptor tyrosine kinase, Ron.
INTRODUCTION
Receptor tyrosine kinases (RTKs) can be regulated by PTPs
(protein tyrosine phosphatases [1]) in many ways. PTPs may
inactivate the RTKs, thus terminating stimulation by the ligand
[2]. Alternatively, PTPs may modulate receptor kinase activity or
its signalling pathway in ligand-dependent or -independent ways
[1,2]. One example is PTP-S, the phosphatase that we found to
interact with the HGF (hepatocyte growth factor) receptor Met
[3,4]. The association was stimulated by HGF and involved a
juxtamembrane tyrosine residue which contributed to the negative
Met regulation [4].
RTKs also contain several serine and threonine residues, some
of which are located within consensus sequences for known
kinases. There is increasing evidence that serine/threonine phos-
phorylation plays a relevant role in modulating RTK functions
[5–7]. For instance, phosphorylation inhibits the tyrosine kinase
activity of insulin [5], epidermal growth factor [6] and HGF
[7] receptors. Alternatively, phosphorylated serine residues may
provide docking sites for binding proteins mediating the down-
stream receptor signalling [8].
In contrast, nothing is known about the serine/threonine phos-
phatases that dephosphorylate the RTKs. Two enzymes that are
probably involved are PP1 (protein phosphatase 1) and PP2A
[9,10]. These are two phosphatase families that regulate a variety
of signalling pathways (see below). To tackle this problem, we
used the MSP (macrophage-stimulating protein) receptor Ron,
an RTK displaying several serine and threonine residues in its
cytosolic domain [11,12]. Ron belongs to the HGF receptor
family and is involved in a wide spectrum of biological activities,
including mitogenesis, apoptosis and cell motility [11,13]. Ron
signalling occurs after phosphorylation of a multifunctional
tyrosine docking site and association of multiple effectors [13].
Abbreviations used: Akt/PKB, protein serine/threonine kinase B; FCS, foetal calf serum; HGF, hepatocyte growth factor; LB broth, Luria–Bertani broth;
PP2A, protein phosphatase 2A; PTP, protein tyrosine phosphatase; RTK, receptor tyrosine kinase; MSP, macrophage-stimulating protein; GST, glutathione
S-transferase.
1 To whom correspondence should be addressed (e-mail villa@biomed.unipi.it).
It has been demonstrated recently that MSP stimulation induces
phosphorylation of Ser-1394 [14]. This serine residue is located
at the C-terminus of Ron and is highly conserved in human, rat
and mouse homologues, but not in Met. Phosphorylation of
Ser-1394 occurs via MSP-dependent activation of the phospho-
inositide 3-kinase–Akt pathway [14]. Akt/PKB (protein serine/
threonine kinase B), a kinase involved in cell proliferation, sur-
vival and migration [15], recognizes Ser-1394 and its surrounding
sequence as an optimal phosphorylation site (RXRXXS) [14].
After phosphorylation, Ser-1394 becomes a docking site for 14-3-
3 (scaffold proteins binding to phosphoserine/phosphothreonine-
containing sequences) [14]. These are scaffold proteins and co-
factors that bind to phosphoserine/phosphothreonine-containing
sequences and thus regulate the subcellular localization or
functions of target proteins [16]. The interaction of 14-3-3 with
Ron induces a multiprotein complex, containing Ron, 14-3-
3 and the α6β4 integrin [14]. This complex, in turn, down-
regulates the α6β4-dependent adhesion and favours migration.
Such a mechanism is involved in keratinocyte migration and re-
epithelization during wound healing [14].
PP1 is present in virtually all cell compartments, suggesting its
involvement in several different cellular functions [9,10,17–20].
The holoenzyme consists of a catalytic subunit bound to a reg-
ulatory subunit [10]. Various unrelated regulatory subunits have
been described previously [10]. The regulatory subunits mod-
ulate the enzymic activity and target the enzyme to specific
functions [10,17]. In mammalian cells, three highly homologous
isoforms of the PP1 catalytic subunit exist, namely α, γ 1 and δ
(also called β) [9,19]. Isoform-specific antibodies (see e.g. [18])
were used to study the differential association and localization of
the isoforms [18,20–22].
In the present study, we show that PP1 associates with and
dephosphorylates Ron Ser-1394, both in vitro and in living cells.
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This association is ligand- or serum-dependent and modulates the
interaction of 14-3-3 with Ron in a negative way.
EXPERIMENTAL
Antibodies, purified proteins and chemicals
PP1 isoform-specific antibodies were raised in rabbits injected
with peptides derived from the C-termini of the three PP1 iso-
forms [18]. Anti-PP2A polyclonal antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Anti-Ron
polyclonal antibodies were raised as described previously [11].
Phospho-Ser-1394-specific antibodies were raised to the Ron-
derived phosphopeptide (N-NVRRPRPLpSEPPRPT-C; Euro-
gentec, Seraing, Belgium) coupled with keyhole-limpet (Diodora
aspera) haemocyanin (Sigma) and were affinity-purified [14].
Akt phospho-Ser-473-specific polyclonal antibodies and anti-Akt
antibodies were obtained from Cell Signaling Technology
(Beverly, MA, U.S.A.) and anti-pan-14-3-3 monoclonal anti-
bodies from Upstate Biotechnology (Lake Placid, NY, U.S.A.).
Recombinant MSP was obtained from R&D Systems
(Minneapolis, MN, U.S.A.). PP1 and PP2A were purified from
rabbit muscle as isolated catalytic subunits, as described by Resink
et al. [23]. Wortmannin and okadaic acid were obtained from
Sigma.
DNA constructs and cell expression
Full-length Ron [11] and Tpr-Ron [24,25] were subcloned into the
pMT2 vector and expressed transiently in COS-1 cells, using
the CellPhect transfection kit (Amersham Biosciences). NIH-
3T3-fibroblast stable cell lines, expressing either wild-type Ron
or the S1394A mutant full-length Ron, were obtained by co-trans-
fection of each recombinant plasmid cDNA [14] with pSV2-neo
plasmid (in the ratio 15:1) using the CellPhect transfection kit.
Subsequent selection was performed in growth medium sup-
plemented with 0.4 mg/ml geneticin sulphate (G418; Sigma).
Stable cell-culture clones expressing the same level of the
respective recombinant proteins were selected by Western-blot
analysis using specific C-terminal Ron antibodies [11]. GST-
fusion proteins of C-terminal Ron (residues 1350–1400) and of
its S1394A mutant were described previously [14].
Cell culture and extracts
NIH-3T3 fibroblasts, GTL-16 gastric carcinoma cell line and
COS-1 cells were grown in Dulbecco’s modified Eagle’s medium
(Sigma) supplemented with 10 % (v/v) FCS (foetal calf serum;
Invitrogen) at 37 ◦C in a 5 % CO2 water-saturated atmosphere
[20]. Cells were lysed in cell lysis buffer [25 mM Hepes,
pH 7.4/10 % (v/v) glycerol/100 mM NaCl/5 mM MgCl2/1 mM
EGTA/1 % Triton X-100], containing 7.5 mM 2-mercaptoe-
thanol, 5 µg/ml L-1-p-tosylamino-2-phenethyl chloromethane,
4 µg/ml leupeptin, 10 µg/ml soya-bean trypsin inhibitor, 40 µg/
ml PMSF and 20 µg/ml benzamidine. The extracts were clarified
by centrifugation at 10 000 g for 10 min and stored at − 80 ◦C.
Metabolic labelling of cells
The culture medium was changed to H3PO4-free medium (Sigma)
containing 10 % H3PO4-free FCS. After 1 h, the medium was
changed to the same medium supplemented with [32P]H3PO4
(1 mCi/150 mm plate in 1 ml medium; Amersham Biosciences)
and left for an additional 5 h [20]. To preserve serine and threo-
nine phosphorylations, the extraction buffer also contained 1 µM
okadaic acid (Sigma), whereas tyrosine phosphatase inhibitors
were absent, to allow tyrosine dephosphorylation [20]. In some
experiments, the cells were additionally treated with 20 or 200 nM
okadaic acid during the last 30 min of labelling.
Immunoprecipitation and immunoblotting
Immunoprecipitates were prepared with anti-Ron rabbit serum
(5 µl/ml cell extract) or anti-PP1 (α, γ 1 or δ) rabbit sera (10 µl/
ml) and Protein A–Sepharose (Sigma) [18]. After incubation at
4 ◦C for 90 min with shaking and three washes with wash buffer
(50 mM Hepes, pH 7.4/100 mM NaCl/300 mM sucrose/5 mM
MgCl2/5 mM EGTA), containing 20 µg/ml PMSF and 20 µg/ml
benzamidine, the immunocomplexes were boiled in Laemmli
buffer. For further PP1 treatment, the immunocomplexes were
washed once again with 25 mM imidazole (pH 7.5), resuspended
in 25 µl of the same buffer containing 2 mM 2-mercaptoethanol,
incubated with purified PP1 [23] as specifically indicated,
and boiled in Laemmli buffer. Electrophoresis was on 8.5 or
12.5 % SDS/polyacrylamide gels and Immobilon-P (Millipore,
Billerica, MA, U.S.A.) was used for transblotting. The mem-
branes were probed with the indicated antibodies diluted in
2.5 % (w/v) BSA/Tris-buffered saline, followed by Protein A–
peroxidase or anti-mouse IgG–peroxidase and the enhanced
chemiluminescence system (Amersham Biosciences). For re-
probing with a second antibody, the membranes were incubated
previously in 5 mM phosphate buffer, 2 % (w/v) SDS and 2 mM
2-mercaptoethanol at 60 ◦C for 30 min [18]. For autoradiography,
the membranes were dried and exposed to Hyperfilms-MP
(Amersham Biosciences) at − 80 ◦C, using intensifying screens.
Two-dimensional phospho-amino-acid analysis
Phosphoproteins, transferred on to Immobilon-P, were hydrolysed
in 6 M HCl at 110 ◦C for 1 h and analysed as described by Kamps
[26].
Bacterial culture, extracts and in vitro association
Bacteria were grown at 37 ◦C in LB (Luria–Bertani) broth
containing 50 µg/ml ampicillin, induced with 0.1 mM isopropyl
β-D-thiogalactoside for 2 h and extracted as described previously
[20]. The GST (glutathione S-transferase)-fusion proteins from
bacterial extracts were bound to 25–50 µl of glutathione–
Sepharose beads (Amersham Biosciences). After 90 min rotation
at 4 ◦C and three washes with 50 mM Tris (pH 7.5), supplemented
with 0.25 % Triton X-100, 20 µg/ml benzamidine and 20 µg/ml
PMSF, the beads were Akt-phosphorylated (see below) and
incubated with purified PP1 (diluted in cell-lysis buffer). Further
processing was the same as described for immunoprecipitation
and blotting.
In vitro phosphorylation of Ron by Akt
C-terminal Ron (either GST-fusion protein bound to glutathione–
Sepharose beads or after removal of GST by thrombin [14]) or
Ron immunoprecipitated from cell extract was resuspended in
25 mM Tris (pH 7.5), 10 mM MgCl2, 5 mM MnCl2, 400 µM
[γ -32P]ATP (3000 c.p.m./pmol) and 7.5 mM 2-mercaptoethanol
and incubated with 2 units of purified Akt (Cell Signaling
Technology) at 30 ◦C for 20 min. This was followed by the ad-
dition of 10 mM EDTA (final concentration) and processing as
specifically indicated in the Figure legends.
In vitro dephosphorylation of Ron by PP1
Ron immunocomplexes prepared from in vivo-labelled cells
or Ron phosphorylated in vitro by Akt were washed with 25 mM
c© 2003 Biochemical Society
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imidazole (pH 7.5), resuspended in 25 µl of the same buffer and
incubated with 1–5 units of purified PP1 [23] at 30 ◦C for 30 min.
This was followed by boiling in Laemmli buffer and processing
as described for immunoblotting and autoradiography.
Phosphatase assay
Immunocomplexes were prepared as indicated above, washed
with 25 mM imidazole (pH 7.5) and resuspended in 25 µl of
25 mM imidazole and 50 mM 2-mercaptoethanol. The reaction
was started by adding 25 µl of 3 mg/ml [32P]phosphorylase a, run
for 20 min at 30 ◦C and stopped by adding cold 10 % (w/v)
trichloroacetic acid [20]. Okadaic acid (5 nM) was present in
the assays [20], a concentration that did not affect PP1, but
inhibited PP2A to > 95 %, according to a preliminary test using
muscle-purified phosphatases. The phosphatase activity was cal-
culated from the [32P]H3PO4 released from the substrate, after
subtracting the c.p.m. of control immunocomplexes, which were
prepared using preimmune serum and run in parallel. The phos-
phatase activity is given as (fmol of Pi released from the
substrate) · min−1 · (mg of cell extract used for immunopreci-
pitation)−1.
RESULTS
Ron serine phosphorylation and dephosphorylation by PP1
Ron displays several serine and threonine residues that may
undergo phosphorylation [11,12], thus becoming potential targets
for PP1. To investigate the serine/threonine phosphorylation of
Ron, cells were metabolically labelled with [32P]H3PO4 and lysed
in the absence of tyrosine phosphatase inhibitors (thus favouring
tyrosine dephosphorylation). Ron was found to be phosphorylated
(Figure 1A) and phospho-amino-acid analysis detected only
phosphoserine (Figure 1B). The phosphorylation decreased after
incubation of the Ron immunocomplex with a PP1 catalytic
subunit (purified from muscle [23]; Figure 1A). These results
indicate that Ron represents a potential PP1 substrate.
Detection of the Ron-associated PP1
The presence of an associated PP1 was investigated in Ron
immunoprecipitated from epithelial and fibroblast cell lines. The
associated phosphatase activity was assayed with the exogenous
substrate phosphorylase a. The assay was selective for PP1,
because it was run under the following conditions: (i) in the
presence of 5 nM okadaic acid (a concentration that did not affect
PP1, but inhibited PP2A to > 95 %, according to a preliminary
test on muscle-purified phosphatases) and (ii) in the absence of
Mg2+ or Ca2+ (ions required by other PP2 types). Moreover, the
same activity values were obtained in assays run in the presence
or absence of okadaic acid. This indicated that no PP2A was
present in the immunocomplexes (results not shown). The Ron-
associated PP1 activity was detected in Ron-expressing NIH-3T3
fibroblasts (Figure 2A). The activity was also detected in COS-1
cells transiently expressing Ron (either as an entire receptor
or as constitutively active chimaera Tpr-Ron [25]; results not
shown) and in the gastric carcinoma GTL-16 cells (expressing
endogenous Ron; results not shown).
To confirm the identity of PP1, Ron immunocomplexes from
GTL-16 cells were probed with the isoform-specific anti-PP1
antibodies [18]. PP1α and PP1γ 1 were detected, whereas PP1δ
was absent (Figure 2B). This result may apply also to the other
cell lines examined, since the three PP1 isoforms are present in
Figure 1 Ron serine phosphorylation and dephosphorylation by PP1
(A) GTL-16 cells were metabolically labelled with [32P]H3PO4 and Ron was immunoprecipitated
(ip Ron) from the cell extract (3 mg/immunoprecipitation) in duplicate. One immunocomplex
was treated with 1 unit of muscle-purified PP1 catalytic subunit at 30 ◦C for 20 min (PP1+).
Both samples were subjected to SDS/PAGE and transblotted on to Immobilon-P. The blot was
first probed with the anti-Ron antibodies (Ron blot), and then exposed to detect the radioactivity
incorporated into Ron (Autorad.). (B) The Ron protein (ip Ron, PP1−) was excised from the
blot, hydrolysed and subjected to two-dimensional phospho-amino-acid analysis, to detect
the radioactivity incorporated into phosphoserine (S), phosphothreonine (T) and phospho-
tyrosine (Y).
all mammalian cells. On the other hand, the use of anti-PP2A
antibodies confirmed the absence of PP2A from the Ron im-
munocomplex (results not shown).
PP1 association with Ron is induced by MSP
The next step was to investigate whether the Ron–PP1 association
was constitutive or functionally correlated with Ron. Stimulation
of Ron by MSP activates the tyrosine kinase and its downstream
signalling [27]. To verify whether MSP influences the PP1 as-
sociation, Ron-expressing NIH-3T3 fibroblasts were serum-
starved and then exposed to MSP. Serum-starvation for 12 h
decreased the Ron-associated PP1 activity to the level of non-
transfected cells. Subsequent exposure to MSP for 15 min restored
the associated PP1 activity (Figure 2A). The association of PP1 in
response to MSP was confirmed also by detection of the PP1 pro-
tein (Figure 2C). We conclude that PP1 associates with Ron after
serum or MSP stimulation.
To test whether the interaction is transient or sustained, Ron-
expressing NIH-3T3 fibroblasts were serum-starved and exposed
to MSP for up to 90 min. The cells were collected as indicated
and lysed. Ron was immunoprecipitated and the associated PP1
activity was assayed on the immunocomplexes. Results indicated
that the association was maximal at 15 min and then decreased
(Figure 3A). The association of PP1 in response to MSP and the
subsequent dissociation were confirmed by immunoblotting. In
most of the experiments (one of which is shown in Figure 3B),
the PP1 protein was clearly detected only at 15 and 30 min, the
time points when the maximal PP1 activity was assayed. This
indicates that the changes induced by MSP in associated PP1
activity were due to reversible association of PP1 rather than to
changes in the specific activity of a constitutively bound PP1.
MSP stimulation induces phosphorylation of Ser-1394
Among the Ron serine residues, Ser-1394 was recently shown
to be a substrate for Akt [14]. Therefore Ser-1394 phosphory-
lation and Akt activation were analysed by immunoblotting in
Ron-expressing NIH-3T3 cells. In serum-starved cells, Akt was
not active (based on the absence of Akt Ser-473 phosphorylation)
and Ron Ser-1394 was not phosphorylated. MSP stimulation
induced both Ser-1394 phosphorylation and Akt activation.
c© 2003 Biochemical Society
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Figure 2 Association of PP1 with Ron and stimulation by MSP
(A) Ron-expressing NIH-3T3 fibroblasts (Ron+) were either grown in a medium containing 10 %
FCS (FCS+) or serum-starved for 12 h (FCS−), and further treated with 100 ng/ml recombinant
MSP for 15 min (MSP+). Mock-transfected NIH-3T3 fibroblasts were used as controls
(Ron−). Ron was immunoprecipitated from the cell extracts (3 mg/immunoprecipitation) and the
associated PP1 activity was assayed. PP1 activity is given as (fmol of Pi released) · min−1 · (mg
of cell extract)−1. Control immunoprecipitates (prepared with unrelated IgGs) were run in parallel
with each sample and assayed for PP1. The activity assayed on each control (between 0 and
30 fmol · min−1 · mg−1) was subtracted from the activity assayed on the corresponding anti-
Ron immunoprecipitate, to obtain the indicated activities. Results are means +− S.E.M. from
five determinations. (B) Three sets of immunoprecipitates were prepared with anti-Ron (ip
Ron) or preimmune serum (ip PI) from GTL-16 cell extracts. The three blots obtained were
probed with anti-α, anti-γ 1 and anti-δ antibodies, as indicated. Lanes α, γ 1 and δ, 20 ng
of recombinant PP1 catalytic subunits. After electrophoresis and transblotting, the blots were
probed with the indicated anti-PP1 isoform antibodies. (C) Ron was immunoprecipitated from
Ron-expressing NIH-3T3 cells. The cells were either serum-starved (MSP−) or MSP-treated
(MSP+), as described in (A). The blots were probed to detect PP1 (PP1 blot) using a mixture
of the three isoform-specific antibodies. This was followed by removal of the antibodies and
re-probing with the anti-Ron antibodies (Ron blot). Other experimental details are as described
in (B).
Phosphorylation of both sites was maximal at 15 min and then
decreased (Figure 4A). This kinetics parallels the kinetics of PP1
interaction with Ron (Figure 3), suggesting the involvement of
Ser-1394 phosphorylation in the interaction.
Figure 3 Time course of the MSP-stimulated association of PP1 with Ron
(A) Ron-expressing NIH-3T3 cells were serum-starved for 12 h (zero time) and further treated
with MSP, as described in the legend to Figure 2(A). Cells were collected at the indicated time
points. PP1 activity was assayed on anti-Ron and control immunocomplexes, as described in
the legend to Figure 2(A). Results are means +− S.E.M. from five determinations. (B) Cells were
treated as in (A) and collected at the indicated time points. Ron was immunoprecipitated from
the cell extracts and the blot obtained was probed to detect PP1 and Ron, as described in the
legend to Figure 2(C).
To characterize the correlation between Akt activation and
Ser-1394 phosphorylation, Ron-expressing NIH-3T3 cells were
treated with wortmannin, a phosphoinositide 3-kinase inhibitor.
Wortmannin prevented both Akt activation and Ser-1394 phos-
phorylation (Figure 4B). Most significantly, a total loss of Ron-
associated PP1 occurred after wortmannin treatment (Figure 4C;
see also Figure 6C, which displays detection of PP1). This
result further supported the hypothesis that phospho-Ser-1394
is involved in PP1 association.
Role of Ser-1394 in Ron–PP1 interaction in vitro
The role of Ser-1394 in PP1 binding was first tested in an in vitro
binding assay, using purified PP1 catalytic subunit and GST–Ron
(a fusion protein reproducing the last 50 C-terminal residues of
wild-type Ron) or its S1394A mutant. GST–Ron was able to bind
the PP1 catalytic subunit, whereas GST–Ron S1394A failed to
do so (Figure 5). The binding was performed also with purified
PP2A, which failed to associate with GST–Ron, whether wild-
type or S1394A mutant. These results indicate that Ser-1394 is
required for the in vitro interaction between C-terminal Ron and
the isolated PP1 catalytic subunit.
Role of Ser-1394 in Ron–PP1 interaction in living cells
The subsequent step was to test whether Ser-1394 is also involved
in the interaction with PP1 in living cells, where PP1 is generally
targeted to substrates by a regulatory subunit and Ron is expressed
as an entire receptor. For this purpose, Ron carrying the S1394A
c© 2003 Biochemical Society
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Figure 4 Effects of MSP and wortmannin on Ron Ser-1394 phosphorylation,
Akt activation and Ron–PP1 interaction
(A) Ron-expressing NIH-3T3 cells were serum-starved and subsequently treated with MSP for
a maximum of 60 min (as in Figure 3). Extracts were obtained at each time point and were used
to prepare three separate blots to detect Ron (Ron blot), Ron phospho-Ser-1394 (pSer1394
blot) and Akt phospho-Ser-473 (which indicates Akt activation; pSer473 Akt blot). (B) Ron-
expressing NIH-3T3 cells were treated with or without 100 nM wortmannin for 30 min in the
absence of serum. The extracts obtained were used to prepare four separate blots to detect Ron,
Ron phospho-Ser-1394, Akt protein (Akt blot) and the Akt phospho-Ser-473. (C) Cell extracts
obtained as in (B) were used to immunoprecipitate Ron and assay the associated PP1 activity
(as in Figure 2). Results are means +− S.E.M. from three determinations.
Figure 5 Loss of Ron–PP1 interaction in vitro induced by S1394A mutation
GST–C-terminal Ron (residues 1350–1400), either wild-type (Ron) or S1394A mutant (Ron
S1394A) or GST alone, were bound to glutathione–Sepharose beads, phosphorylated in vitro
by Akt (2 units during 20 min incubation at 30 ◦C; see the Experimental section) and were used
to associate either PP1 or PP2A catalytic subunits. The blots obtained were probed with either
anti-PP1 (PP1 blot) or anti-PP2A (PP2A blot) antibodies. Lane PP1+ or PP2A+, 30 ng of
each catalytic subunit.
mutation was stably expressed in NIH-3T3 fibroblasts. Ron and
Ron S1394A from cells grown in the serum were tested for
PP1 binding. Ron S1394A was still associated with PP1 activity,
although less than wild-type Ron (Figure 6A). This was bona fide
PP1 activity, since it was totally inhibited by 0.5 µM okadaic acid
(a concentration that inhibits PP1 completely; results not shown).
Moreover, the presence of PP1 was confirmed by immunoblotting
(Figure 6B). To test whether PP1 was still regulated, serum-
starved cells expressing the S1394A mutant were exposed to
Figure 6 Association of PP1 with the S1394A Ron mutant in living cells
(A) Ron or the S1394A Ron mutant were stably expressed in NIH-3T3 fibroblasts. Cells were
either serum-starved for 12 h (Ron− FCS and S1394A− FCS) or grown in medium containing
10 % FCS (Ron+FCS and S1394A+FCS) or serum-starved for 12 h and further treated
with 100 ng/ml recombinant MSP for 15 min (Ron+MSP and S1394A+MSP). Ron was
immunoprecipitated from the cell extracts and the associated PP1 activity was assayed. PP1
was assayed also on control immunoprecipitates, as described in the legend to Figure 2. Results
are means +− S.E.M. from four determinations. (B) Cells expressing Ron or the S1394A Ron
mutant were either serum-starved (MSP−) or serum-starved and further treated with MSP
(MSP+), as described in (A). The extracts were used to immunoprecipitate Ron and the blot
obtained was probed to detect the Ron-associated PP1 (PP1 blot). Aliquots of these extracts
were also used to prepare three additional blots to detect Ron (Ron blot), Ron phosphotyrosine
(pTyr Ron blot) and Ron phospho-Ser-1394 (pSer1394 blot). Other experimental details are as
described in the legend to Figure 2. (C) Cells expressing Ron or the S1394A Ron mutant were
treated with or without wortmannin, as in Figure 4(B). Ron was immunoprecipitated from the cell
extracts and the blot obtained was probed to detect PP1 and Ron, as described in the legend to
Figure 2(C).
MSP. The mutant-associated PP1 activity was neither decreased
by serum starvation nor increased by MSP treatment (Figure 6A).
The loss of response to serum starvation and MSP treatment was
confirmed by immunoblotting (Figure 6B). The results could not
be attributed to differential expression of the receptor, because
the two cell lines expressed similar receptor levels (see the
Experimental section). Moreover, both Ron forms were activated
by MSP, as shown by the increase in tyrosine phosphorylation ob-
served after ligand exposure (Figure 6B). Also the sensitivity to
wortmannin was lost, since the Ron-S1394A-associated PP1 did
not dissociate after cell treatment with wortmannin (Figure 6C).
Altogether, the results indicate that, in living cells, PP1 still
interacts with the Ron mutant S1394A, but no longer responds to
the regulatory signals. This, in turn, indicates the involvement of
Ser-1394 in PP1 binding and suggests a functional link between
PP1 and Ron within the ligand-stimulated Ron signalling.
c© 2003 Biochemical Society
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Figure 7 Dephosphorylation of Ron by PP1 in vitro and in living cells
(A) C-terminal Ron was phosphorylated in vitro in triplicate by Akt (2 units) during 20 min
incubation at 30 ◦C (Ron+Akt). After the addition of 10 mM EDTA (final concentration) to all
the samples and 1 or 5 units of muscle-purified PP1, as indicated, the samples were further
incubated at 30 ◦C for 20 min. The blot obtained was probed to detect the site phosphorylated
by Akt using anti-phospho(Ser/Thr) Akt substrate antibodies. (B) Ron, immunoprecipitated
in duplicate from serum-starved NIH-3T3 cell extract, was phosphorylated in vitro by Akt (ip
Ron+Akt) and treated with or without 1 unit of PP1, as described in (A). The blot obtained was
first probed with the anti-Ron antibodies (Ron blot). This was followed by re-probing with the
anti-pSer-1394 antibodies (pSer1394 blot) and exposure to detect the radioactivity incorporated
into Ron (Autorad.). (C) Ron was immunoprecipitated in duplicate from metabolically labelled
NIH-3T3 cells (as in Figure 1) and treated with or without 1 unit of PP1. The blot obtained was
probed to detect Ron, phospho-Ser-1394 and radioactivity, as described in (B). (D) Metabolically
labelled cells were exposed to the indicated amounts of okadaic acid during the last 30 min
of labelling. Ron was immunoprecipitated and the blot obtained was probed to detect Ron,
pSer-1394 and radioactivity.
Dephosphorylation of Ser-1394 by PP1
The consequent step was to investigate the ability of PP1 to de-
phosphorylate Ser-1394. This was first tested in vitro, using either
C-terminal Ron or cellular Ron. C-terminal Ron was phosphory-
lated in vitro by Akt and subsequently treated with 1 or 5 units
of purified PP1. Phosphorylation was detected using phospho-
specific antibodies recognizing phosphorylated Akt substrates.
Of the two PP1 amounts used, 5 units of PP1 dephosphorylated
Ser-1394 almost completely (Figure 7A). Alternatively, Ron was
immunoprecipitated from serum-starved cells and phosphorylated
in vitro by Akt, in the presence of [γ -32P]ATP. As expected, Ron
was phosphorylated at Ser-1394. Subsequent treatment with
muscle-purified PP1 removed the phosphate from Ser-1394
almost completely (Figure 7B). In another experiment, Ron was
phosphorylated at Ser-1394 during [32P]H3PO4 metabolic label-
ling, performed in the presence of 10% serum. The subsequent
PP1 treatment in vitro dephosphorylated Ser-1394 completely
(Figure 7C).
The involvement of PP1 in Ser-1394 dephosphorylation was
then tested in living cells. For this purpose, the Ron-expressing
NIH-3T3 cells were treated with the phosphatase inhibitor
okadaic acid. This was used at 20 nM, a concentration that in-
hibits PP2A only, and at 200 nM, a concentration that inhibits
both PP1 and PP2A [28]. Cells were metabolically labelled with
Figure 8 Modulation of the Ron–14-3-3 association by PP1
(A) GTL-16 cell extract was used to immunoprecipitate Ron in duplicate (ip Ron). One immuno-
complex was further treated with 1 unit of PP1 catalytic subunit, as in Figure 1. After electro-
phoresis and transblotting, the blot was probed with anti-pan-14-3-3 antibodies (14-3-3 blot),
followed by re-probing with the anti-Ron antibodies (Ron blot). (B) Ron was immunoprecipitated
from GTL-16 cells treated with or without 200 nM okadaic acid for 60 min. Other experimental
details are as described in (A).
[32P]H3PO4 and exposed to okadaic acid during the last 30 min
of labelling. Ron immunoprecipitated from cells treated with
200 nM okadaic acid was phosphorylated more when compared
with Ron immunoprecipitated from cells untreated or treated with
20 nM okadaic acid. Specifically, the increase in Ron phosphory-
lation involved Ser-1394 (Figure 7D). This last result indirectly
indicates the involvement of PP1 in Ron Ser-1394 dephosphory-
lation in living cells.
PP1 influences the association of 14-3-3 with Ron
Once phosphorylated by Akt, Ser-1394 provides a docking site
for 14-3-3. Consequently, we investigated the ability of PP1 to
influence such binding in vitro and in living cells. As expected,
Ron immunoprecipitated from cells grown in the serum displayed
associated 14-3-3 (Figure 8A; [14]). Treatment of the Ron
immunocomplex with PP1 dissociated 14-3-3 almost completely.
This indicated the ability of PP1 to compete with 14-3-3 for the
Ser-1394 site, at least in vitro. On the other hand, treatment of
the cells with 200 nM okadaic acid, a concentration that was able
to inhibit PP1, increased the amount of associated 14-3-3 (Fig-
ure 8B). This confirmed the ability of PP1 to recognize this site
as a substrate and indicated that PP1 may be the enzyme counter-
acting the effects of Akt on Ser-1394 phosphorylation in living
cells.
DISCUSSION
Several tyrosine phosphatases may associate with RTKs, either in
response to ligand stimulation or in a ligand-independent manner
[1–4]. In the present study, we have shown that a serine/threonine
phosphatase associates with an RTK, namely the tyrosine kinase
Ron. The interaction occurs after receptor activation through both
MSP-dependent and -independent mechanisms.
The finding that PP1 associates with Ron in cells of different ori-
gins prompted us to characterize this association. We found
that, in cells expressing wild-type Ron, PP1 binding is not con-
stitutive, but transient. The interaction occurs after ligand acti-
vation of Ron or after Akt kinase-activating signals. Very little PP1
co-immunoprecipitates with Ron from serum-starved cells, when
little or no Ser-1394 phosphorylation is detected. MSP treatment
rescues PP1 to the same level observed in cells grown in the serum.
Furthermore, the association is transient and its kinetics parallels
the kinetics of Ser-1394 phosphorylation. To our knowledge, this
is the first report on the association of PP1 with a growth factor
receptor and of its regulation by the ligand.
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Ser-1394 has been characterized recently as a specific phospho-
serine docking site, generated after Ron activation by MSP [14].
This is in addition to the well-known phosphotyrosine multi-
functional docking site, surrounding Tyr-1353 and Tyr-1360
[13,27]. This new serine site resides within a consensus sequence
for Akt [14]. Most remarkably, phosphorylated Ser-1394 binds
proteins of the 14-3-3 family [14]. In turn, 14-3-3 may form
a multiprotein complex with the α6β4 integrin, which down-
regulates the α6β4-dependent adhesion [14]. These results and
their implication in cell migration and in re-epithelization during
wound healing were reported previously [14].
The involvement of Ser-1394 in the interaction with PP1 is
suggested by the fact that, in vitro, the association between isolated
catalytic subunit and C-terminal Ron occurs only when Ser-1394
is preserved. The specificity is further highlighted by the fact
that PP2A fails to interact with C-terminal Ron. The picture
is more complex in living cells, where Ron is expressed as an
entire receptor. Ron mutation does not prevent PP1 interaction,
but its regulation is completely lost. PP1 neither dissociates from
S1394A-Ron after serum starvation or wortmannin treatment nor
responds to MSP, as it does with wild-type Ron. PP1 seems to be
trapped on the mutated receptor in an active, de-regulated state.
A possible interpretation of these results assumes the presence of
a regulatory subunit, as it is generally the case with PP1 [10]. The
function of the regulatory subunits is to target PP1 to substrates
and to modulate the enzymic activity [10]. It is possible that,
for the S1394A-Ron, the regulatory subunit still anchors PP1 to
the mutated receptor. However, the absence of the target serine
residue would prevent a proper response to the regulatory signals.
Identification of the regulatory subunit of the Ron-directed PP1
may help to clarify this mechanism. Within this picture, the
association may also involve a Ron site that binds the PP1-
regulatory subunit. Such a site might be located outside the C-
terminus of Ron and it might play a role only in living cells,
where the entire receptor is expressed. This hypothesis may help
to explain the discrepancy between the results obtained in vitro
and in living cells.
The loss of PP1 function is only one of the consequences of the
S1394A mutation. The mutation was also reported to induce
the loss of MSP- and Akt-dependent association of 14-3-3 with
Ron, thus hampering the Ron–α6β4 integrin interaction and the
consequent modulation of cell adhesion [14].
PP1 binding is presumably followed by Ser-1394 dephosphory-
lation. This hypothesis is supported by the increase in phospho-
Ser-1394 after cell exposure to an okadaic acid concentration
that inhibits PP1. This result indicates that the Ser-1394-directed
PP1 is active in cells grown in the serum. PP1 inhibition by
okadaic acid shifts the balance towards Ser-1394 phosphorylation.
In principle, under such conditions, the binding of 14-3-3 to
Ser-1394 should also be favoured [14]. Indeed, we showed that
okadaic acid treatment increased also the Ron-associated 14-3-
3. Altogether, the results define a role for PP1 in balancing the
effects of Ser-1394 phosphorylation by Akt within the serum- and
MSP-dependent signalling.
Phosphorylation of specific serine and threonine sites of RTKs
has been linked to the negative regulation of the receptors. For
instance, phosphorylation of Ser-654 of the epidermal growth
factor receptor [6] or Ser-985 of the HGF receptor [7] inhibited
the receptor kinase activity and its biological effects. In this
case, the function of the phosphatase was to remove the inhibitory
effect of phosphorylation, thus contributing to receptor activation.
Alternatively, serine phosphorylation may generate docking sites
for effectors, thus sustaining the downstream signalling of specific
pathways. For Ron, Ser-1394 phosphorylation by Akt generates
a docking site for 14-3-3 [14]. Within this picture, the role of the
phosphatase might be to modulate or terminate the downstream
signalling generated at this site.
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